Lb Pharmaceuticals (LBRX) Gains from Investment Securities (2024 - 2025)
Lb Pharmaceuticals' quarterly Gains from Investment Securities came in at $1.8 million in Q3 2025, up 1.21% quarter-over-quarter from $1.8 million in Q4 2024.
Lb Pharmaceuticals has reported Gains from Investment Securities for 2 years, with the latest figure at $1.8 million in Q3 2025.
- For the quarter ending Q3 2025, Gains from Investment Securities changed N/A year-over-year to $1.8 million; the trailing twelve-month figure through Sep 2025 stood at $1.8 million (changed N/A YoY), and the FY2025 full-year result was $2.6 million, up 466.3% from the prior year.
- Gains from Investment Securities for Q3 2025 stood at $1.8 million, up from $1.8 million in the prior quarter.
- The five-year high for Gains from Investment Securities was $1.8 million in Q3 2025, with the low at $1.8 million in Q4 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | Lb Pharmaceuticals | 789.92 Mn | 789.92 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 1.83 Mn |
| Sep 30, 2025 | 1.83 Mn |
| Dec 31, 2024 | 1.81 Mn |
| Dec 31, 2024 | 1.81 Mn |